Deans' stroke musings: Vascular diseases await translation of blood vessels engineered from stem cells

Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Thursday, October 15, 2015

Vascular diseases await translation of blood vessels engineered from stem cells

We need this to support new neurons from neurogenesis and from whenever we get neuronal stem cells implanted.
http://stm.sciencemag.org/content/7/309/309rv6.abstract?

Rekha Samuel¹,²,
Dan G. Duda¹,
Dai Fukumura¹ and
Rakesh K. Jain¹,*

+ Author Affiliations

↵*Corresponding author. E-mail: jain@steele.mgh.harvard.edu

Science Translational Medicine 14 Oct 2015:
Vol. 7, Issue 309, pp. 309rv6
DOI: 10.1126/scitranslmed.aaa1805

You are currently viewing the abstract.
View Full Text

Abstract

The discovery of human induced pluripotent stem cells (hiPSCs) might pave the way toward a long-sought solution for obtaining sufficient numbers of autologous cells for tissue engineering. Several methods exist for generating endothelial cells or perivascular cells from hiPSCs in vitro for use in the building of vascular tissue. We discuss current developments in the generation of vascular progenitor cells from hiPSCs and the assessment of their functional capacity in vivo, opportunities and challenges for the clinical translation of engineered vascular tissue, and modeling of vascular diseases using hiPSC-derived vascular progenitor cells.